Principles of psychoneuroendocrinoimmunotherapy of cancer

Immunotherapy

Volumn 4, Issue 1, 2012, Pages 77-86

  Lissoni, Paolo ^a   Rovelli, Franco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

cannabinergic system; neuroimmunomodulation; opioid system; pineal gland; psychoncology

Indexed keywords

5 METHOXYTRYPTAMINE; ALPHA INTERFERON; CISPLATIN; DOPAMINE; FLUOROURACIL; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 2; MELATONIN; NALTREXONE; PINEAL BODY HORMONE;

ADULT RESPIRATORY DISTRESS SYNDROME; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CAPILLARY LEAK SYNDROME; CONTINUOUS INFUSION; CYTOTOXIC LYMPHOCYTE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNOMODULATION; IN VIVO STUDY; LOW DRUG DOSE; NEOPLASM; NEUROENDOCRINE SYSTEM; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; TUMOR IMMUNITY;

5-METHOXYTRYPTAMINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENDOCANNABINOIDS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MELATONIN; NALTREXONE; NEOPLASMS; NEUROSECRETORY SYSTEMS;

EID: 83655182338     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.158     Document Type: Review

References (65)

1. Broder S, Muul L, Waidmann TA. Suppressor cells in neoplastic disease. J. Natl Cancer Inst. 61, 5-11 (1978). (Pubitemid 8382784)
2. Chouaib S, Fradelizi D. The mechanism of inhibition of human IL 2 production. J. Immunol. 129, 2463-2467 (1982).
3. Foon KA. Biological response modifiers: The new immunotherapy. Cancer Res. 49, 1621-1627 (1989).
4. Woijtowicz-Praga S. Reversal of tumor-induced immunosuppression: A new approach to cancer therapy. J. Immunother. 20, 165-177 (1997).
5. Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat. Rev. Immunol. 6, 295-307 (2006).
6. Rosenberg SA. The immunotherapy and gene therapy of cancer. J. Clin. Oncol. 10, 180-199 (1992).
7. Hurwitz H, Feherenbacher L, Novothy W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004). (Pubitemid 38702844)
8. Saltz LB, Meropol NJ, Loehre PJ et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J. Clin. Oncol. 22, 1201-1208 (2004). (Pubitemid 41079832)
9. Riesco A. Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer 25, 135-140 (1970).
10. Lissoni P, Fumagalli L, Rovelli F, Brivio F, Di Felice G, Majorca F. In vivo stimulation of IL 12 secretion by subcutaneous low-dose IL 2 in metastatic cancer patients. Br. J. Cancer 77, 1957-1960 (1998). (Pubitemid 28254639)
11. Antoni M, Lutgendorf S, Cole S et al. The influence of behavioural factors on tumor biology: pathways and mechanisms. Nat. Rev. Cancer 6, 240-248 (2006). (Pubitemid 43292567)
12. Costanzo ES, Sood AK, Lutgendorf SK. Biobehavioral influences on cancer progression. Immunol. Allergy Clin. North Am. 31, 109-132 (2011).
13. Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune mechanisms of behavioural comorbidities in patients with cancer. J. Clin. Oncol. 26, 971-982 (2008). (Pubitemid 351409339)
14. Jankovic BD. Neuroimmunomodulation. From phenomenology to molecular evidence. Ann. NY Acad. Sci. 741, 3-38 (1994).
15. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. J. Exp. Med. 155, 1823-1841 (1982).
16. Banks R, Patel PM, Selby PJ. Interleukin 12: A new clinical player in cytokine therapy. Br. J. Cancer 71, 655-659 (1995).
17. Kasid A, Bell GI, Director EP. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors: Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J. Immunol. 141, 690-695 (1988).
18. Moore KW, O'Garra A, de Waal-Malefyt R, Vieira P, Mosman TR. Interleukin 10. Ann. Rev. Immunol. 11, 165-172 (1993).
19. Kunutso KL, Disis ML, Salazar LG. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol. Immun. 556, 2471-2485 (2007).
20. Battelli E, Oukka M, Kuchroo VK. TH 17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8, 345-350 (2007).
21. Peters J, Gieseler R, Thiele B, Steinbach F. Dendritic cells: From ontogenic orphans to myelomonocytic descendants. Immunol. Today 17, 277-278 (1996).
22. Kishimoto T. The biology of interleukin 6. Blood 74, 1-10 (1989).
23. Fumagalli L, Lissoni P, Di Felice G et al. Pretreatment serum markers and lymphocyte response to interleukin 2 therapy. Br. J. Cancer 80, 407-411 (1998).
24. Schwartz RH. Natural regulatory T cells and self-tolerance. Nat. Immunol. 6, 326-330 (2005).
25. 25+ regulatory T cells in patients treated with high-dose interleukin 2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol. 24, 1169-1177 (2006). (Pubitemid 46638815)
26. Gabrilovich SI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumor inhibits the functional maturation of dendritic cells. Nat. Med. 2, 1096-1103 (1996). (Pubitemid 26338628)
27. Westphal M, Li CH. Beta-endorphin: Characterization of binding sites specific for the human hormone in human glioblastoma SF 126 cells. Proc. Natl Acad. Sci. USA 81, 2921-2924 (1984).
28. Dewey WL. Cannabinoid pharmacology. Pharmacol. Rev. 38, 151-178, (1986). (Pubitemid 16001329)
29. Grotenhermen F. Pharmacology of cannabinoids. Neuroendocrinol. Lett. 25, 14-22 (2004).
30. Brzezinski A. Melatonin in humans. N. Engl. J. Med. 336, 186-195 (1997). (Pubitemid 27034965)
31. Lewis JW, Shavit Y, Terman GW, Gale RP, Liebeskind JC. Apparent involvement of opioid peptides in stress-induced enhancement of tumor growth. Peptides 4, 635-641 (1983).
32. Plotnikoff NP, Miller GC. Enkephalins as immunomodulators. Int. J. Immunopharmacol. 5, 437-442 (1983).
33. Mathews PM, Froelich CJ, Sibbit WL Jr, Bankurst AD. Enhancement of natural cytotoxicity by beta-endorphin. J. Immunol. 130, 1658-1662 (1983).
34. Lissoni P, Resentini M, Mauri R et al. Effects of tetrahydrocannabinol on melatonin secretion in man. Horm. Metab. Res. 18, 77-78 (1986). (Pubitemid 16187083)
35. Maestroni JGM. The immunoneuroendocrine role of melatonin. J. Pineal Res. 14, 1-10 (1993).
36. Sze SF, Ng TB, Liu WK. Antiproliferative effect of pineal indoles on cultured tumor cell lines. J. Pineal Res. 14, 27-33 (1993). (Pubitemid 23149257)
37. Beck O, Jonsonn G, Lundman A. 5 methoxyindoles in pineal gland of cow, pig, sheep and rat. Arch. Pharmacol. 318, 49-52 (1981).
38. Eck KM, Yuan L, Duffy L et al. A sequential treatment regimen with melatonin and all-trans retinoic acid induces apoptosis in MCF 7 tumor cells. Br. J. Cancer 77, 2129-2137 (1998). (Pubitemid 28263932)
39. Lissoni P, Pittalis S, Rovelli F et al. Interleukin 2, melatonin and interleukin 12 as a possible neuroimmune combination in the biotherapy of cancer. J. Biol. Regul. Homeost. Agents 9, 63-66 (1995). (Pubitemid 26096012)
40. Lissoni P. Is there a role for melatonin in supportive care? Supp. Care Cancer 10, 110-116 (2000).
41. Lissoni P, Mandalà M, Mandelli A, Fumagalli L. Neuroimmunotherapy with subcutaneous low-dose interleukin 2 plus the pineal oncostatic hormones melatonin and 5 methoxytryptamine in untreatable advanced solid neoplasm patients with poor clinical status. Int. J. Immunother. XV, 35-38 (1999). (Pubitemid 29363959)
42. Lissoni P, Cangemi P, Pirato D et al. A review on cancer-psychospiritual status interactions. Neuroendocrinol. Lett. 22, 175-180 (2001). (Pubitemid 32677237)
43. Bartsch C, bartsch H, Lippert TH. The pineal gland and cancer : Facts, hypotheses and perspectives. Cancer J. 5, 194-199 (1992).
44. Mazzoccoli G, Carughi S, De Cata A et al. Neuroendocrine alterations in lung cancer patients. Neuroendocrinol. Lett. 24, 77-82 (2003). (Pubitemid 36559505)
45. Mazzoccoli G, Fontana A, Copetti M et al. Stage-dependent destructuration of neuro-endocrine-immune system components in lung cancer patients. Biomed. Pharmacother. 65, 69-76 (2011).
46. Holtkamp WS, Nagel CA, Wander HE, Rauschecker HF, Heyden D. Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int. J. Cancer 34, 323-328 (1984).
47. Katsumada N, Eguchi K, Fukuda M, Yamamoto N, Ohe N, Oshita F. Serum levels of cytokines in patients with untreated primary lung cancer. Clin. Cancer Res. 2, 553-559 (1996). (Pubitemid 26099175)
48. Mormont MC, Levi F. Circadian system alterations during cancer processes: A review. Int. J. Cancer 70, 241-247 (1997). (Pubitemid 27107423)
49. Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J. Clin. Oncol. 26, 971-982 (2008). (Pubitemid 351409339)
50. Brivio F, Fumagalli L, Parolini D et al. T helper/T regulator lymphocyte ratio as a new immunobiologial index to quantify the anticancer immune status in cancer patients. In Vivo 22, 647-650 (2008).
51. Wittington R, Faulds D. Interleukin 2. Drugs 46, 4466-483 (1993).
52. Atzpodien J, Kirchner H. Cancer, cytokines and cytotoxic cells. Klin. Wochenschr. 68, 1-11 (1990).
53. Lissoni P, Barni S, Ardizzoia A et al. Second line therapy with low-dose subcutaneous interleukin 2 alone in advanced renal cancer patients resistant to interferon-alpha. Eur. J. Cancer 28, 92-96 (1992).
54. Recchia F, Saggio G, Nuzzo A et al. Multicentric phase 2 study of interleukin 2 and 13 cis retinoic acid as maintenance therapy in advanced non-small cell lung cancer. J. Immunother. 29, 87-94 (2006).
55. Bernengo MG, Quaglino O, Cappello N et al. Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin 2-based chemoimmunotherapy in advanced metastatic melanoma patients. Melanoma Res. 10, 55-65 (2000). (Pubitemid 30127830)
56. Wigginton JM, Komschlies KL, Black TC et al. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J. Natl Cancer Inst. 88, 38-43 (1996). (Pubitemid 26006869)
57. Lissoni P, Pittalis S, Brivio F et al. In vitro modulatory effects of interleukin 3 on macrophage activation induced by interleukin 2. Cancer 71, 2076-2081 (1993). (Pubitemid 23068559)
58. Conti A, Maestroni GJM. The clinical neuroimmunotherapeutic role of melatonin in oncology. J. Pineal Res. 19, 103-110 (1995).
59. Lissoni P, Barni S, Tancini G et al. A randomized study with subcutaneous low-dose interleuikin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br. J. Cancer 69, 196-199 (1994). (Pubitemid 24021848)
60. Lissoni P, Brivio F, Fumagalli L et al. Neuroimmunomodulation in medical oncology: Application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. Anticancer Res. 28, 1377-1382 (2008).
61. El-Domeiri AAH, Das Gupta TK. Reversal by melatonin of the effect of pinealectomy on tumor growth. Cancer Res. 33, 2830-2833 (1973).
62. Vasin MV, Lvova TS, Antipov VV, Davydon BI. Anti-radiation effectiveness of cystamine and mexamine on mouse hematopoietic stem cells in vivo. Radiobiologia 17, 254-258 (1977). (Pubitemid 8085182)
63. Zagon IS, Verderame MF, Hankins J, McLaughlin PJ. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer. Int. J. Cancer 30, 775-783 (2007).
64. Lissoni P, Meregalli S, Fossati V et al. Radioendocrine therapy of brain tumors with the long-acting opioid antagonist naltrexone in association with radiotherapy. Tumori 79, 198-201 (1993). (Pubitemid 23338106)
65. Wybran J, Appelboom T, Famaey JP, Govaerts A. Suggestive evidence for morphine and methionine-enkephalin receptors on normal T lymphocytes. J. Immunol. 123, 1068-1072 (1979).